Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cell Cycle

• Publication date

  2011-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cc.10.16.16952PMID 21822052PMCID PMC3233494
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.

  2011cited by this paper
• A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells

  2011cited by this paper
• Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas

  2011cited by this paper
• Differential regulation of the proapoptotic multidomain protein Bak by p53 and p73 at the promoter level

  2011cited by this paper
• TRAIL/TRAIL‐R in hematologic malignancies

  2010cited by this paper
• A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies

  2010cited by this paper
• Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

  2010cited by this paper
• Death Receptor Agonists as a Targeted Therapy for Cancer

  2010cited by this paper
• Characterization and expression analyses of anti-apoptotic Bcl-2-like genes NR-13, Mcl-1, Bcl-X1, and Bcl-X2 in Atlantic cod (Gadus morhua).

  2010cited by this paper
• A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

  2010cited by this paper
• New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence.

  2010cited by this paper
• Targeting mitochondria for cancer therapy

  2010cited by this paper
• A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells.

  2010cited by this paper
• Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer

  2009cited by this paper
• Mcl-1 is a potential therapeutic target in multiple types of cancer

  2009cited by this paper
• Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax.

  2009cited by this paper
• Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions

  2009cited by this paper
• Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

  2009cited by this paper
• A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes

  2009cited by this paper
• Pathophysiological roles of osteoprotegerin (OPG).

  2009cited by this paper
• TRAIL receptor signalling and modulation: Are we on the right TRAIL?

  2009cited by this paper
• Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1.

  2009cited by this paper
• Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy

  2009cited by this paper
• BH3 Mimetic Obatoclax Enhances TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells

  2009cited by this paper
• Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells1

  2008cited by this paper
• TRAIL and cancer therapy.

  2008cited by this paper
• Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

  2008cited by this paper
• The NF-κB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs

  2008cited by this paper
• BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells

  2008cited by this paper
• A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells

  2008cited by this paper
• BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis

  2008cited by this paper
• Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

  2007cited by this paper
• Regulation of Tumor Cell Sensitivity to TRAIL-Induced Apoptosis by the Metastatic Suppressor Raf Kinase Inhibitor Protein via Yin Yang 1 Inhibition and Death Receptor 5 Up-Regulation

  2007cited by this paper
• Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1

  2007cited by this paper
• Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma.

  2007cited by this paper
• The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.

  2007cited by this paper
• Targeting NF-κB and induction of apoptosis by novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells

  2007cited by this paper
• Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

  2007cited by this paper
• Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.

  2007cited by this paper
• Involvement of the TNF-α autocrine–paracrine loop, via NF-κB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis

  2006cited by this paper
• Bcl2's Flexible Loop Domain Regulates p53 Binding and Survival

  2006cited by this paper
• Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.

  2006cited by this paper
• The Bad Guy Cooperates with Good Cop p53: Bad Is Transcriptionally Up-Regulated by p53 and Forms a Bad/p53 Complex at the Mitochondria To Induce Apoptosis

  2006cited by this paper
• Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia.

  2005cited by this paper
• Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor

  2005cited by this paper
• Mechanisms of resistance to TRAIL-induced apoptosis in cancer

  2005cited by this paper
• BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly.

  2005cited by this paper
• Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.

  2004cited by this paper
• Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance

  2004cited by this paper
• Transcriptional Regulation of the BCL-X Gene by NF-κB Is an Element of Hypoxic Responses in the Rat Brain

  2004cited by this paper
• Inhibition of Transcription Factor Activity by Nuclear Compartment-associated Bcl-2*

  2004cited by this paper
• Missing pieces in the NF-kappaB puzzle.

  2002cited by this paper
• Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

  2002cited by this paper
• NF-kappaB signaling. Many roads lead to madrid.

  2002cited by this paper
• The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells.

  2002cited by this paper
• BID regulation by p53 contributes to chemosensitivity

  2002cited by this paper
• Molecular design and biological activities of NF-kappaB inhibitors.

  2002cited by this paper
• Transcriptional regulation of the BCL-X gene by NF-kappaB is an element of hypoxic responses in the rat brain.

  2001cited by this paper
• Suppression of transcription factor NF-kappaB activity by Bcl-2 protein in NIH3T3 cells: implication of a novel NF-kappaB p50-Bcl-2 complex for the anti-apoptotic function of Bcl-2.

  2000cited by this paper
• Death and decoy receptors and p53-mediated apoptosis

  2000cited by this paper
• NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes.

  1999cited by this paper
• Cytokine induced expression of porcine inhibitor of apoptosis protein (iap) family member is regulated by NF-kappa B.

  1998cited by this paper
• Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis

  1996cited by this paper
• Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*

  1996cited by this paper
• Inhibition of NF‐kappaB/Rel induces apoptosis of murine B cells.

  1996cited by this paper
• A method for testing for synergy with any number of agents.

  1978cited by this paper

• Targeting the YY1-Bcl2-c-Myc Axis in the treatment of non-Hodgkin lymphoma.

  2025cites this paper
• Yin Yang 1 (YY1) as a Central Node in Drug Resistance Pathways: Potential for Combination Strategies in Cancer Therapy

  2025cites this paper
• Targeting YY1-DR5 Axis by Pyripyropene O as a Novel Therapeutic Strategy Against Prostate Cancer: Molecular Mechanisms and In Vivo Zebrafish Validation

  2025cites this paper
• Obatoclax enhances TRAIL-induced apoptosis in non-small-cell-lung-cancer cells by increasing TRAIL receptor expression, priming for mitochondrial apoptosis and reducing XIAP levels

  2025cites this paper
• Therapeutic Implications of Targeting YY1 in Glioblastoma

  2024cites this paper
• Role of YY1 in the Regulation of Anti-Apoptotic Gene Products in Drug-Resistant Cancer Cells

  2023cites this paper
• Roles and Regulation of BCL-xL in Hematological Malignancies

  2022influential citation
• RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity

  2021cites this paper
• Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives

  2021cites this paper
• Yin Yang 1 regulation of tumor cell resistance to chemotherapeutic drugs

  2021cites this paper
• Participation of different miRNAs in the regulation of YY1: Their role in pathogenesis, chemoresistance, and therapeutic implication in hematologic malignancies

  2021cites this paper
• BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma

  2020cites this paper
• Salinomycin inhibits epigenetic modulator EZH2 to enhance Death Receptors in Colon Cancer Stem Cells

  2020cites this paper
• Therapeutic targeting of SNAIL, RKIP, and YY1 in tumor metastasis and drug resistance

  2020cites this paper
• Obatoclax, a Pan-BCL-2 Inhibitor, Downregulates Survivin to Induce Apoptosis in Human Colorectal Carcinoma Cells Via Suppressing WNT/β-catenin Signaling

  2020cites this paper
• Elucidation for modulation of death receptor (DR) 5 to strengthen apoptotic signals in cancer cells

  2019cites this paper
• The Two Sides of YY1 in Cancer: A Friend and a Foe

  2019cites this paper
• RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact

  2018cites this paper
• Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

  2018cites this paper
• CRHR2/Ucn2 signaling is a novel regulator of miR‐7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas‐mediated apoptosis

  2018cites this paper
• miR-29a suppresses IL-13-induced cell invasion by inhibiting YY1 in the AKT pathway in lung adenocarcinoma A549 cells

  2018cites this paper
• Sensitivity and Resistance to BH3 Mimetics in Cancer Therapy

  2018cites this paper
• University of Groningen Trail receptor-targeted therapy : strategies to enhance DR 4-and DR 5-induced apoptosis

  2017cites this paper
• Bayesian Network Inference Modeling Identifies TRIB1 as a Novel Regulator of Cell-Cycle Progression and Survival in Cancer Cells.

  2017influential citation
• The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization

  2016cites this paper
• BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia

  2016cites this paper
• Survival control of malignant lymphocytes by anti-apoptotic MCL-1

  2016cites this paper
• Non-canonical NF-κB Plays a Pivotal Role in Non-Hodgkin’s Lymphoma

  2015cites this paper
• Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage

  2015cites this paper
• Inhibition of MCL‐1 by obatoclax sensitizes Sp2/0‐Ag14 hybridoma cells to glutamine deprivation‐induced apoptosis

  2015cites this paper
• Two death-inducing human TRAIL receptors to target in cancer: similar or distinct regulation and function?

  2014cites this paper
• Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways

  2014cites this paper
• Pan-Bcl-2 Inhibitor Obatoclax Delays Cell Cycle Progression and Blocks Migration of Colorectal Cancer Cells

  2014cites this paper
• Gene set enrichment analysis of the NF-κB/Snail/YY1/RKIP circuitry in multiple myeloma

  2014cites this paper
• Trail receptor-targeted therapy : strategies to enhance DR4- and DR5-induced apoptosis

  2014cites this paper
• Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells.

  2014cites this paper
• Trail receptor-targeted therapy : strategies to enhance DR4-and DR5-induced apoptosis

  2014cites this paper
• Leading Small Molecule Inhibitors of Anti-Apoptotic Bcl-2 Family Members

  2013cites this paper
• Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis.

  2013cites this paper
• Ubiquitous transcription factor YY1 promotes zebrafish liver steatosis and lipotoxicity by inhibiting CHOP-10 expression.

  2013cites this paper
• Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer.

  2013cites this paper
• An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies

  2013cites this paper
• Towards targeted therapy of chronic lymphocytic leukemia.

  2013cites this paper
• Bcl-2 antagonists: a proof of concept for CLL therapy

  2013cites this paper
• Inhibiting mitochondrial-dependent proteolysis of Mcl-1 promotes resistance to DNA damage

  2012cites this paper
• Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms

  2012cites this paper
• Glucose—a sweet way to die

  2012cites this paper
• Transcription regulator Yin-yang 1: from silence to cancer.

  2011cites this paper